Johnson & Johnson (JNJ) Q3 2025 Earnings
How Did JNJ Stock React to Q3 2025 Earnings?
S&P 500 over the same 30 days: +1.48%.
Did JNJ Beat Earnings? Q3 2025 Results
Yes. Johnson & Johnson reported Q3 2025 earnings of $2.80 a share on Oct 14, 2025, beating the $2.76 consensus estimate by 1.5%. Revenue was $24.0B against a $23.8B estimate.
Johnson & Johnson posted a clean beat across the board in Q3 2025, reporting adjusted diluted EPS of $2.80 against a consensus of $2.76 — a 1.49% beat — while revenue of $23.99 billion edged past estimates by 1.00% and climbed 6.8% year over year. The headline numbers were powered by a pharmaceutical portfolio firing on multiple cylinders: DARZALEX surged 21.7% to $3.67 billion, TREMFYA jumped 41.3% to $1.42 billion, and cell therapy CARVYKTI nearly doubled, rising 83.5% to $524 million — more than offsetting the continued erosion of STELARA to biosimilar competition, which fell 41.3% to $1.57 billion. MedTech contributed $8.43 billion in sales, with Cardiovascular leading at $2.21 billion on 12.6% growth. The quarter's most consequential development was J&J's announcement that it intends to spin off its DePuy Synthes orthopaedics unit within 18 to 24 months, a move designed to sharpen focus on higher-growth segments — a <a href="https://247wallst.com/investing/2026/01/10/the-glp-1-blockbuster-maker-widens-its-lead-as-the-diversified-healthcare-giant-posts-steady-growth/">meaningful strategic shift</a> as diversified healthcare giants reposition their portfolios. Management raised full-year 2025 sales guidance to approximately $93.70 billion while reaffirming adjusted EPS guidance of $10.85 at the midpoint.
- DARZALEX growth of 21.7% driven by continued market expansion in multiple myeloma
- TREMFYA growth of 41.3% driven by new indications and market share gains in immunology
- CARVYKTI growth of 83.5% as CAR-T cell therapy adoption accelerates in oncology
- SPRAVATO growth of 61.5% in treatment-resistant depression
- CAPLYTA contributing $240M from Intra-Cellular Therapies acquisition (April 2025)
- MedTech Cardiovascular growth of 12.6% driven by electrophysiology, Abiomed and Shockwave
- Surgical Vision growth of 14.9%
- Partial offset from STELARA biosimilar erosion (-41.3%) and IMBRUVICA decline (-7.8%)
“Johnson & Johnson delivered another strong performance in the third quarter fueled by the depth and strength of our portfolio and significant progress across our pipeline. With a sharpened focus on the six priority areas of Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision, Johnson & Johnson is in a new era of accelerated growth and innovation, with pioneering treatments that will continue to transform lives.”
Johnson & Johnson CEO, on the earnings call
What Was Johnson & Johnson's Outlook in Q3 2025?
Johnson & Johnson raised its full-year 2025 reported sales guidance to approximately $93.7 billion, representing 5.7% growth at the midpoint (excluding COVID-19 Vaccine). The company reaffirmed full-year adjusted EPS guidance of $10.85 at the midpoint, absorbing higher tax costs. Adjusted operational sales growth guidance is approximately 4.5% at the midpoint. The company is also pursuing separation of its Orthopaedics business (DePuy Synthes) targeting completion within 18 to 24 months, which is expected to increase the remaining company's top-line growth and operating margins.
JNJ YoY Financials
| Metric | Q3 2025 | Q3 2024 | Year over year |
|---|---|---|---|
| Revenue | $24.0B | $22.5B | +6.8% |
| Gross Profit | $16.7B | $15.5B | +7.6% |
| Net Income | $5.2B | $2.7B | +91.2% |
JNJ Revenue by Segment
JNJ Revenue by Geography
Figures from SEC filings and company reports. Not investment advice.